Compare, Analyse RANBAXY LAB (500359 | ) with SUN PHARMA (524715 | SUNPHARMA~EQ)
X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
 
  
Compare another company

  
  

RANBAXY LAB vs SUN PHARMA - Comparison Results

  
  

RANBAXY LAB 
  Change

Ranbaxy is India's top pharmaceutical company, manufacturing and marketing branded generic pharmaceuticals products and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on US and European markets has helped it build deep product pipelines... More


SUN PHARMA 
Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
Stock Price Chart: ranbaxy lab Vs. sun pharma
Loading...
 
 
DO YOU LIKE THESE REPORTS? TELL US!
 Current Valuations
    RANBAXY LAB SUN PHARMA RANBAXY LAB/  
SUN PHARMA  
P/E (TTM) x -83.3 21.5 - View Chart
P/BV x 11.1 5.3 209.9% View Chart
Dividend Yield % 0.0 0.1 -  
 
 Financials
 RANBAXY LAB   SUN PHARMA
  EQUITY SHARE DATA
    RANBAXY LAB SUN PHARMA RANBAXY LAB/ 5-Yr Chart
    Mar-14 Mar-16 SUN PHARMA Click to enlarge
High Rs5251,201 43.7%   
Low Rs254706 36.0%   
Sales per share (Unadj.) Rs313.4117.5 266.8%  
Earnings per share (Unadj.) Rs-25.619.6 -130.8%  
Cash flow per share (Unadj.) Rs-14.423.8 -60.4%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs78.0130.5 59.8%  
Shares outstanding (eoy) m423.322,406.60 17.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.28.1 15.3%   
Avg P/E ratio x-15.248.7 -31.2%  
P/CF ratio (eoy) x-27.140.1 -67.6%  
Price / Book Value ratio x5.07.3 68.3%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m164,8832,294,813 7.2%   
No. of employees `00015.314.7 103.7%   
Total wages/salary Rs m25,77547,971 53.7%   
Avg. sales/employee Rs Th8,672.219,169.8 45.2%   
Avg. wages/employee Rs Th1,684.63,253.0 51.8%   
Avg. net profit/employee Rs Th-709.33,197.9 -22.2%   
 
  INCOME DATA
Net Sales Rs m132,685282,697 46.9%  
Other income Rs m1,8286,170 29.6%   
Total revenues Rs m134,513288,867 46.6%   
Gross profit Rs m9,73283,239 11.7%  
Depreciation Rs m4,76210,135 47.0%   
Interest Rs m5,5734,769 116.9%   
Profit before tax Rs m1,22674,505 1.6%   
Minority Interest Rs m20-11,126 -0.2%   
Prior Period Items Rs m-140-19 750.8%   
Extraordinary Inc (Exp) Rs m-8,643-6,852 126.1%   
Tax Rs m3,3149,349 35.5%   
Profit after tax Rs m-10,85247,159 -23.0%  
Gross profit margin %7.329.4 24.9%  
Effective tax rate %270.412.5 2,155.0%   
Net profit margin %-8.216.7 -49.0%  
 
  BALANCE SHEET DATA
Current assets Rs m70,357308,646 22.8%   
Current liabilities Rs m75,760132,477 57.2%   
Net working cap to sales %-4.162.3 -6.5%  
Current ratio x0.92.3 39.9%  
Inventory Days Days7683 91.6%  
Debtors Days Days5788 64.9%  
Net fixed assets Rs m53,839133,606 40.3%   
Share capital Rs m2,1172,407 87.9%   
"Free" reserves Rs m22,130266,909 8.3%   
Net worth Rs m33,031314,042 10.5%   
Long term debt Rs m24,74431,167 79.4%   
Total assets Rs m139,901542,196 25.8%  
Interest coverage x1.216.6 7.3%   
Debt to equity ratio x0.70.1 754.8%  
Sales to assets ratio x0.90.5 181.9%   
Return on assets %-3.89.6 -39.4%  
Return on equity %-32.915.0 -218.8%  
Return on capital %-3.417.8 -19.2%  
Exports to sales %27.614.0 197.2%   
Imports to sales %6.93.1 219.4%   
Exports (fob) Rs m36,62239,572 92.5%   
Imports (cif) Rs m9,1488,882 103.0%   
Fx inflow Rs m50,93942,171 120.8%   
Fx outflow Rs m23,50521,583 108.9%   
Net fx Rs m27,43420,588 133.3%   
 
  CASH FLOW
From Operations Rs m-35,62467,694 -52.6%  
From Investments Rs m18,320-44,549 -41.1%  
From Financial Activity Rs m10,162-19,243 -52.8%  
Net Cashflow Rs m-7,1433,902 -183.1%  
 
 Share Holding
Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 63.4 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 11.8 23.0 51.3%  
ADR/GDR % 1.5 0.0 -  
Free float % 15.0 8.3 180.7%  
Shareholders   182,721 133,026 137.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
Compare RANBAXY LAB With: WYETH LTD | PIRAMAL ENTERPRISES | NATCO PHARMA | AUROBINDO PHARMA | IPCA LABS
Compare RANBAXY LAB With: MYLAN (US) | ACTAVIS (US) | ADCOCK INGRAM (S. Africa) | TEVA PHARMA (Israel)


Today's Market

Sensex Trades Marginally Higher; Realty Stocks Witness Buying(11:30 am)

After opening the day on a flat note, share markets in India witnessed choppy trades and are presently trading marginally higher. Sectoral indices are trading on a positive note with stocks in the realty sector.

Related Views on News

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Sun Pharma: US Segment Shows Signs of Improvement (Quarterly Results Update - Detailed)

Sep 12, 2016

Sun Pharma has announced its 1QFY17 results. The company has reported 22.7% YoY growth in sales and a growth of 266% in the net profits. Here is our analysis of the results.

Sun Pharma: Acquisition synergies start contributing (Quarterly Results Update - Detailed)

Apr 1, 2016

Sun Pharma has announced its 3QFY16 results. Net sales have grown by 2.3% YoY, while net profits surged by 258% YoY. Here is our analysis of the results.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

Doubled Your Money In D-Mart? Read This Before It's Too Late(Daily Profit Hunter)

Mar 22, 2017

Apurva breaks down the historic performance of initial public offerings in the context of D-Mart.

Why Real Estate Prices are Going Down at a Slow Pace(Vivek Kaul's Diary)

Mar 23, 2017

Many investors have got anchored to a selling price which has got nothing to do with the current state of the real estate market

Why Mutual Fund Investors Should Not Worry About Market High. But...(Outside View)

Mar 22, 2017

PersonalFN provides a prudent investment strategy to invest in mutual funds as market scales a new high.

Bad Loans Inventory Bloats Up(Chart Of The Day)

Mar 18, 2017

This is why RBI's new strategy is ineffective to deal with bad debt menace.

More

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

RANBAXY LAB 5-YR ANALYSIS

Detailed Financial Information With Charts

COMPARE RANBAXY LAB WITH

MARKET STATS